₦12,000 Dialysis, but Why are Kidney Patients Still Struggling?
Many people have kidney disease when they are older.
Nigeria has cut the cost of dialysis in selected federal hospitals from about ₦50,000 to ₦12,000 per session, giving thousands of kidney patients some relief.
But for people living with advanced kidney disease, the reduction does not necessarily make treatment affordable.
The reason is simple: dialysis is not a one-time medical bill.
For a patient whose kidneys can no longer adequately perform their functions, treatment can become a recurring expense involving multiple dialysis sessions, drugs, laboratory tests, medical consultations, transportation and, eventually for some patients, the search for a kidney transplant.
This is why Nigeria’s kidney crisis is increasingly about more than the number of people developing the disease. It is also about whether patients can afford to remain alive after diagnosis.
What does the ₦12,000 subsidy actually cover?
The Federal Government announced the dialysis subsidy in August 2025, reducing the cost of a session in participating federal hospitals from ₦50,000 to ₦12,000.
The Federal Ministry of Health said the pilot was already operating in federal hospitals across the six geopolitical zones, including the National Hospital, Abuja, University College Hospital, Ibadan, University of Benin Teaching Hospital and Federal Medical Centre, Ebute Metta. It also said more hospitals would subsequently be added.
That is a significant reduction.
But ₦12,000 is the price of the subsidised dialysis session, not the total cost of living with kidney failure.
Consider a patient receiving three sessions every week. At ₦12,000 per session, dialysis alone would amount to about ₦36,000 a week, or roughly ₦144,000 over four weeks.
That is before adding medication, blood tests, consultations and transportation.
For families already struggling with food, rent, school fees and other expenses, a recurring medical bill of that size can still be overwhelming.
Why kidney treatment does not end at dialysis
Dialysis performs some of the work normally carried out by healthy kidneys by removing waste and excess fluid from the blood.
But patients may still require other forms of medical care.
They may need regular laboratory tests to monitor their condition, medication to manage complications and consultations with specialists.
Transport can also become a hidden cost.
A patient who needs to visit a hospital several times a week may have to pay for transportation for every appointment. For people living far from a participating federal hospital, the subsidy may reduce the treatment fee while leaving a significant travel burden untouched.
This matters because kidney failure is not a condition that can usually be managed by paying for one hospital visit and returning home.
The treatment has to continue.
The affordability problem existed before the subsidy
Nigeria’s kidney-care problem did not begin with the current economic crisis.
A long-standing challenge has been the inability of many patients to sustain maintenance dialysis.
Nigeria Health Watch reported in 2025 that a study had found only about 2% of people with end-stage kidney disease in Nigeria received haemodialysis, while 80% could not sustain treatment beyond three months because of the cost.
The figures come from an earlier study and should not be treated as a current national estimate, but they illustrate the scale of the affordability problem that policymakers have been trying to address.
The same pattern has appeared in Nigerian medical literature for years: patients may begin dialysis but struggle to continue paying for it.
That creates a particularly cruel problem.
A treatment can be medically available but effectively inaccessible if the patient cannot afford to keep returning.
The subsidy is a major intervention, but it has limits
It would be misleading to describe the government subsidy as ineffective.
Reducing a dialysis session from ₦50,000 to ₦12,000 represents a 76% reduction in the stated session cost.
For a patient who can access the programme, that difference can determine whether treatment is possible.
The Federal Ministry of Health has also described the programme as a safety net and said it would expand the number of participating federal hospitals.
The issue is therefore not whether the subsidy matters.
It does.
The bigger question is whether subsidising the session alone is enough to solve the financial barriers surrounding kidney failure.
For many patients, the answer is no.
Why health insurance matters
Kidney failure exposes one of the biggest weaknesses in healthcare financing: the difficulty of paying for chronic conditions that require long-term treatment.
A person who needs dialysis for months or years cannot realistically be expected to depend on personal savings or relatives indefinitely.
This is where health insurance becomes important.
The National Health Insurance Authority has included haemodialysis within its benefit package, although its published provisions place limits on the number of sessions covered. That means insurance can provide some protection but may not cover the full treatment burden faced by a patient requiring regular dialysis.
The Federal Government has also said it is expanding health insurance coverage as part of its broader healthcare-financing reforms. In 2025, the Health Ministry said insurance enrolment had reached 20 million people, with a target of 44 million by 2030.
For kidney patients, expanding coverage will matter only if the benefits are sufficient to meet the reality of chronic kidney care.
The cheaper treatment may be the treatment that prevents dialysis
There is another part of the kidney crisis that receives less attention: prevention and early detection.
Kidney disease can progress for years without obvious symptoms.
By the time a person develops severe symptoms, kidney function may already have deteriorated significantly.
This makes regular health checks important, particularly for people living with conditions such as high blood pressure and diabetes, which can contribute to kidney damage.
Prevention also includes caution around medicines.
Self-medication and the use of unregulated drugs can create serious health complications. Nigerians who routinely take medicines without proper medical guidance may expose themselves to avoidable risks.
The logic is straightforward: detecting and managing kidney problems early can be far less financially devastating than reaching end-stage kidney failure and requiring long-term dialysis.
The real kidney crisis is sustainability
Nigeria’s ₦12,000 dialysis subsidy has changed the immediate calculation for patients who can access it.
But the broader question remains unanswered: how does a Nigerian family sustain kidney treatment month after month?
That is where the cost of kidney failure becomes much bigger than the price printed on a dialysis bill.
There is the treatment itself.
There are drugs.
There are tests.
There is transportation.
There are specialist appointments.
There may eventually be the cost of pursuing a transplant, followed by lifelong medication if a transplant is successful.
For families without adequate insurance or financial support, the cumulative burden can mean selling assets, borrowing money or relying on donations.
That is why Nigeria’s response to kidney disease cannot stop at subsidising dialysis sessions.
The country needs stronger prevention, earlier diagnosis, wider insurance coverage and a sustainable system for patients who require long-term renal care.
The ₦12,000 price tag is a meaningful intervention.
But for someone whose life depends on returning to the dialysis machine again and again, affordable access is not the same thing as affordable survival.